comparemela.com
Home
Live Updates
Curis Reports First Quarter 2022 Financial Results and Busin
Curis Reports First Quarter 2022 Financial Results and Busin
Curis Reports First Quarter 2022 Financial Results and Business Update
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
Related Keywords
United States ,
American ,
Roche Erivedge ,
James Dentzer ,
American Society Of Clinical Oncology ,
Genentech ,
European Hematology Association ,
Drug Administration ,
Washington University School Of Medicine ,
Nasdaq ,
Curis Inc ,
American Society Of Clinical Oncology Annual Meeting ,
Development Expenses ,
Exchange Commission ,
Prnewswire Curis Inc ,
Roche Group ,
Washington University In St ,
Washington University ,
Chief Executive Officer ,
Recommended Phase ,
Recent Operational ,
Takeaim Leukemia ,
Washington University School ,
Clinical Oncology Annual ,
Hematologic Malignancies ,
Chronic Lymphocytic ,
Poster Discussion ,
Myelodysplastic Syndromes ,
Gastrointestinal Cancer ,
Central Nervous System ,
Planned Milestones ,
Takeaim Lymphoma ,
American Society ,
Clinical Oncology ,
Aim Lymphoma ,
Aim Leukemia ,
Orphan Drug Designation ,
Note Regarding Forward Looking Statements ,
Securities Litigation Reform Act ,
Oberland Capital ,
Curis ,
Nc ,